Dr Reddy's launches Geodon generic in USA
Indian drugmaker Dr Reddy’s Laboratories (BSE: 500124) has announced the launch of ziprasidone mesylate for injection, 20mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon Injection, 20mg/mL, in the USA, where it is approved by the US Food and Drug Administration
Geodon is an antipsychotic drug marketed by US pharma giant Pfizer (NYSE: PFE).
“We’re pleased to bring the first generic of ziprasidone mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” explains Marc Kikuchi, chief executive, America Generics, Dr Reddy’s Laboratories. “This is a great addition to our injectable offering in the US market as we continue to augment our portfolio and drive growth within the hospital segment,” he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze